Melatonin improves experimental colitis with sleep deprivation

International Journal of Molecular Medicine

Volumn 35, Issue 4, 2015, Pages 979-986

  Park, Young Sook ^a   Chung, Sook Hee ^b   Lee, Seong Kyu ^a   Kim, Ja Hyun ^a   Kim, Jun Bong ^a   Kim, Tae Kyun ^a   Kim, Dong Shin ^a   Baik, Haing Woon ^a  

^a Eulji University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Colitis; Melatonin; Sleep deprivation

Indexed keywords

CALMODULIN; CALMODULIN 3; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELATONIN; PROTEIN KINASE C ZETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WNT5A PROTEIN; AUTACOID; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SLEEP DEPRIVATION; SURVIVAL RATE; TREATMENT OUTCOME; WEIGHT REDUCTION; ANIMAL; BODY WEIGHT; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION PROFILING; INTESTINE MUCOSA; METABOLISM; MORTALITY; PATHOLOGY;

ANIMALS; BODY WEIGHT; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; INFLAMMATION MEDIATORS; INTESTINAL MUCOSA; MALE; MELATONIN; MICE; SLEEP DEPRIVATION;

EID: 84923684258     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2080     Document Type: Article

References (44)

1. Langan RC, Gotsch PB, Krafczyk MA and Skillinge DD: Ulcerative colitis: diagnosis and treatment. Am Fam Physician 76: 1323-1330, 2007.
2. Bamias G and Cominelli F: Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol 23: 365-369, 2007.
3. Farrell RJ and Peppercorn MA: Ulcerative colitis. Lancet 359: 331-340, 2002.
4. Niess JH, Mönnikes H, Dignass AU, Klapp BF and Arck PC: Review on the influence of stress on immune mediators, neuropeptides and hormones with relevance for inflammatory bowel disease. Digestion 65: 131-140, 2002.
5. Sonnenberg A: Occupational distribution of inflammatory bowel disease among German employees. Gut 31: 1037-1040, 1990.
6. Necefli A, Tulumoʇlu B, Giriş M, et al: The effect of melatonin on TNBS-induced colitis. Dig Dis Sci 51: 1538-1545, 2006.
7. Mazzon E, Esposito E, Crisafulli C, et al: Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res 41: 363-373, 2006.
8. Li JH, Yu JP, Yu HG, et al: Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm 2005: 185-193, 2005.
9. Nosál'ová V1, Zeman M, Cerná S, Navarová J and Zakálová M: Protective effect of melatonin in acetic acid induced colitis in rats. J Pineal Res 42: 364-370, 2007.
10. Akcan A, Kucuk C, Sozuer E, et al: Melatonin reduces bacterial translocation and apoptosis in trinitrobenzene sulphonic acid-induced colitis of rats. World J Gastroenterol 14: 918-924, 2008.
11. Stebelová K, Herichová I and Zeman M: Diabetes induces changes in melatonin concentrations in peripheral tissues of rat. Neuro Endocrinol Lett 28: 159-165, 2007.
12. Cuzzocrea S, Mazzon E, Serraino I, et al: Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 30: 1-12, 2001.
13. Dong WG, Mei Q, Yu JP, et al: Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol 9: 1307-1311, 2003.
14. Tahan G, Gramignoli R, Marongiu F, et al: Melatonin expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic-acid-induced colitis in rats. Dig Dis Sci 56: 715-720, 2011.
15. van Hulzen ZJ and Coenen AM: Effects of paradoxical sleep deprivation on two-way avoidance acquisition. Physiol Behav 29: 581-587, 1982.
16. Lee YD, Kim JY, Lee KH, et al: Melatonin attenuates lipopolysaccharide-induced acute lung inflammation in sleep-deprived mice. J Pineal Res 46: 53-57, 2009.
17. Levenstein S, Prantera C, Varvo V, et al: Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 95: 1213-1220, 2000.
18. Tang Y, Preuss F, Turek FW, Jakate S and Keshavarzian A: Sleep deprivation worsens inflammation and delays recovery in a mouse model of colitis. Sleep Med 10: 597-603, 2009.
19. Swanson GR, Burgess HJ and Keshavarzian A: Sleep disturbances and inflammatory bowel disease: a potential trigger for disease flare? Expert Rev Clin Immunol 7: 29-36, 2011.
20. Boye B, Lundin KE, Jantschek G, et al: INSPIRE study: does stress management improve the course of inflammatory bowel disease and disease-specific quality of life in distressed patients with ulcerative colitis or Crohn's disease? A randomized controlled trial. Inflamm Bowel Dis 17: 1863-1873, 2011.
21. Lerner AB, Case JD, Lee TH and Mori W: Isolation of melatonin, the pineal factor that lightens melanocytes. J Am Chem Soc 80: 2587, 1958.
22. Bubenik GA: Thirty four years since the discovery of gastrointestinal melatonin. J Physiol Pharmacol 59 (Suppl 2): S33-S51, 2008.
23. Thor PJ, Krolczyk G, Gil K, Zurowski D and Nowak L: Melatonin and serotonin effects on gastrointestinal motility. J Physiol Pharmacol 58 (Suppl 6): S97-S103, 2007.
24. Chen CQ, Fichna J, Bashashati M, Li YY and Storr M: Distribution, function and physiological role of melatonin in the lower gut. World J Gastroenterol 17: 3888-3898, 2011.
25. Esposito E, Mazzon E, Riccardi L, et al: Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J Pineal Res 45: 166-173, 2008.
26. Winiarska K, Fraczyk T, Malinska D, Drozak J and Bryla J: Melatonin attenuates diabetes-induced oxidative stress in rabbits. J Pineal Res 40: 168-176, 2006.
27. Mei Q, Yu JP, Xu JM, et al: Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol Sin 23: 882-886, 2002.
28. Ranjbaran Z, Keefer L, Farhadi A, et al: Impact of sleep disturbances in inflammatory bowel disease. J Gastroenterol Hepatol 22: 1748-1753, 2007.
29. Keefer L, Stepanski EJ, Ranjbaran Z, Benson LM and Keshavarzian A: An initial report of sleep disturbance in inactive inflammatory bowel disease. J Gastroenterol Hepatol 2: 409-416, 2006.
30. Bergmann BM, Gilliland MA, Balzano S, Refetoff S and Rechtschaffen A: Sleep deprivation in the rat: XIX. Effects of thyroxine administration. Sleep 18: 317-324, 1995.
31. Trivedi PP and Jena GB: Melatonin reduces ulcerative colitis-associated local and systemic damage in mice: investigation on possible mechanisms. Dig Dis Sci 58: 3460-3474, 2013.
32. Westbrook AM, Wei B, Hacke K, et al: The role of tumour necrosis factor-α and tumour necrosis factor receptor signalling in inflammation-associated systemic genotoxicity. Mutagenesis 27: 77-86, 2012.
33. Arthur JC, Perez-Chanona E, Mühlbauer M, et al: Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338: 120-123, 2012.
34. Reyland ME: Protein kinase C isoforms: Multi-functional regulators of cell life and death. Front Biosci (Landmark Ed) 14: 2386-2399, 2009.
35. Means AR, VanBerkum MF, Bagchi I, Lu KP and Rasmussen CD: Regulatory functions of calmodulin. Pharmacol Ther 50: 255-270, 1991.
36. Kankuri E, Asmawi MZ, Korpela R, Vapaatalo H and Moilanen E: Induction of iNOS in a rat model of acute colitis. Inflammation 23: 141-152, 1999.
37. You J, Nguyen AV, Albers CG, Lin F and Holcombe RF: Wnt pathway-related gene expression in inflammatory bowel disease. Dig Dis Sci 53: 1013-1019, 2008.
38. Du Q, Park KS, Guo Z, et al: Regulation of human nitric oxide synthase 2 expression by Wnt beta-catenin signaling. Cancer Res 66: 7024-7031, 2006.
39. Pereira CP, Bachli EB and Schoedon G: The wnt pathway: a macrophage effector molecule that triggers inflammation. Curr Atheroscler Rep 11: 236-242, 2009.
40. Baert F, Vermeire S, Noman M, et al: Management of ulcerative colitis and Crohn's disease. Acta Clin Belg 59: 304-314, 2004.
41. Malhotra S, Bhasin D, Shafiq N and Pandhi P: Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond. Expert Opin Pharmacother 5: 329-334, 2004.
42. Chojnacki C, Wisniewska-Jarosinska M, Walecka-Kapica E, et al: Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol 62: 327-334, 2011.
43. Rakhimova O: Use of melatonin in combined treatment for inflammatory bowel diseases. Ter Arkh 82: 64-68, 2010 (In Russian).
44. Motilva V, Garcia-Maurino S, Talero E and Illanes M: New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin. J Pineal Res 51: 44-60, 2011.